Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $8.18 million for the quarter.
Fennec Pharmaceuticals Stock Performance
Shares of NASDAQ FENC traded down $0.13 during mid-day trading on Tuesday, hitting $6.15. The stock had a trading volume of 3,194 shares, compared to its average volume of 105,070. The company has a 50 day moving average of $5.98 and a two-hundred day moving average of $5.84. Fennec Pharmaceuticals has a twelve month low of $3.96 and a twelve month high of $10.07. The firm has a market cap of $169.73 million, a PE ratio of -61.50 and a beta of 0.32.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on FENC shares. HC Wainwright reiterated a "buy" rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Tuesday, March 11th. Wedbush reaffirmed an "outperform" rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, March 10th.
Check Out Our Latest Analysis on Fennec Pharmaceuticals
Insiders Place Their Bets
In other news, Director Rosty Raykov sold 10,000 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total transaction of $67,900.00. Following the completion of the sale, the director now owns 68,725 shares of the company's stock, valued at $466,642.75. The trade was a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 41,186 shares of company stock worth $258,189. Company insiders own 10.98% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
